The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or immune-targeted cancer therapies improves the outcome of individual patients and increases the chances of successful drug approval. However, for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.

中文翻译：

---

癌症治疗中缺少目标


指示对肿瘤靶向或免疫靶向癌症疗法敏感性的分子生物标志物的部署可改善个体患者的结果并增加药物成功批准的机会。然而，对于许多致命的恶性肿瘤，大多数临床试验都是针对没有生物标志物的患者进行的，因此他们错过了目标。